2024
Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
Cosgun K, Robinson M, Agadzhanian N, Berning P, Fonseca-Arce D, Leveille E, Kothari S, Davids M, Jellusova J, Müschen M. Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies. Blood 2024, 144: 1412. DOI: 10.1182/blood-2024-208598.Peer-Reviewed Original ResearchProtein degradationRepression of MYCTranscriptional repression of MYCTranscriptional repressionPromote survivalProteasome inhibitorsProtein degradation pathwaysCell typesN-terminal residuesInduce cell deathRefractory B-cell malignanciesB-cateninB-cell malignanciesRNAi screenInteractome studiesB cell selectionRepressive complexesGene dependenciesProteasomal degradationB cellsChemogenomic screensProteasome inhibitor bortezomibActivated mycDeletion of Ctnnb1Cell death
2018
Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models
Kothari S, Mavis C, Gu J, Hernandez-Ilizaliturri F. Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models. Blood 2018, 132: 2942. DOI: 10.1182/blood-2018-99-116510.Peer-Reviewed Original ResearchMantle cell lymphomaAnti-tumor activityPre-clinical modelsRefractory mantle cell lymphomaB-cell lymphoma patientsPrimary tumor cellsMCL cell linesCell cycle regulatory proteinsResistant cell linesProteasome inhibitorsHBL-2 cellsLymphoma patientsCycle regulatory proteinsSCID miceSCID animalsCell linesAutologous stem cell rescueTumor cellsHigh-dose chemotherapyStem cell rescueSignificant anti-tumor activitySynergistic activityNovel therapeutic strategiesNovel proteasome inhibitorSelective BCL-2 inhibitor